Abeona Therapeutics Inc vs Xcel Energy Inc — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Xcel Energy Inc trades at $78.06 (market cap $48.51B). The key difference: Xcel Energy Inc is far larger — about 115.2× Abeona Therapeutics Inc's market cap, and Xcel Energy Inc pays a 3.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | XEL | |
|---|---|---|
Market Cap | $421.19M | $48.51B |
Sector | Health | Utilities |
52-Week High | $7.45 | $83.91 |
52-Week Low | $4.17 | $71.75 |
Enterprise Value | $276.10M | $86.82B |
Dividend Yield | — | 3.05% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Xcel Energy (XEL) trades at $76.87, down 1.54% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, and maintains a solid dividend. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%, while analyst consensus is bullish with a $93.80 price target.
The outlook is supported by earnings growth and a $60 billion capital investment plan, but risks include regulatory pushback and high debt levels. The stock offers a stable investment opportunity with growth potential from infrastructure spending, though affordability concerns and interest rate sensitivity pose challenges.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →